Takamatsu Hiroyuki, Yoroidaka Takeshi, Fujisawa Momoko, Kobori Kazuya, Hanawa Masako, Yamashita Takeshi, Murata Ryoichi, Ueda Mikio, Nakao Shinji, Matsue Kosei
Department of Hematology and Respirology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Cellular Immunology Analysis Section, Genetic and Chromosome Analysis Department, SRL, Inc, Tokyo, Japan.
Int J Hematol. 2019 Apr;109(4):377-381. doi: 10.1007/s12185-019-02615-z. Epub 2019 Feb 18.
We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. The SRL-Flow sample preparation protocol was identical to that of EuroFlow-NGF. The antibody panel for SRL-Flow was as follows: CD138/CD27/CD38ME (multiepitope)/CD56/CD45/CD19/cytoplasmic (Cy) immunoglobulin (Ig) κ/CyIgλ. To identify abnormal plasma cells (aPCs) of patients with MM who received anti-CD38 monoclonal antibody, we used a panel of anti-CD45 and anti-CD138 antibodies (Abs) rather than a panel of anti-CD45 and anti-CD38 Abs. We comparatively analyzed the total nucleated cell numbers, total PC levels, and MRD levels between the SRL-Flow and EuroFlow-NGF. High correlations (r > 0.9) in total PC and MRD levels were noted among SRL-Flow, original EuroFlow-NGF (2 tubes), and EuroFlow-NGF (tube 2 only), suggesting that SRL-Flow is an inexpensive (< $200 USD/sample as of January of 2019) alternative to EuroFlow-NGF (< $350 USD/sample) for assessing MRD in MM.
我们试图确定一种新的、价格低廉的单管8色多参数流式细胞术（MFC）方法（SRL-Flow）的疗效，该方法基于EuroFlow下一代流式检测（仅管2），用于评估微小残留病（MRD）阴性状态。MRD阴性状态被认为是多发性骨髓瘤（MM）治疗的一个里程碑。我们使用了45例MM患者的骨髓样本，其中11例接受了抗CD38单克隆抗体治疗。SRL-Flow样本制备方案与EuroFlow-NGF相同。SRL-Flow的抗体组合如下：CD138/CD27/CD38多表位/CD56/CD45/CD19/细胞质（Cy）免疫球蛋白（Ig）κ/CyIgλ。为了识别接受抗CD38单克隆抗体治疗的MM患者的异常浆细胞（aPC），我们使用了一组抗CD45和抗CD138抗体，而不是一组抗CD45和抗CD38抗体。我们比较分析了SRL-Flow和EuroFlow-NGF之间的总核细胞数、总浆细胞水平和MRD水平。在SRL-Flow、原始EuroFlow-NGF（2管）和EuroFlow-NGF（仅管2）之间，总浆细胞和MRD水平存在高度相关性（r > 0.9），这表明SRL-Flow是一种价格低廉（截至2019年1月，< 200美元/样本）的替代方法，可用于替代EuroFlow-NGF（< 350美元/样本）来评估MM中的MRD。
